Open AccessA Rare Lymphoproliferative Disease: Castleman Disease
Author(s) -
Eren Gündüz,
Nihal Özdemir,
Şule Mine Bakanay,
Sema Karakuş
Publication year - 2021
Publication title -
turkish journal of hematology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.351
H-Index - 16
ISSN - 1300-7777
DOI - 10.4274/tjh.galenos.2021.2021.0440
Subject(s) - medicine , paraneoplastic pemphigus , poems syndrome , pathology , castleman disease , hyaline , generalized lymphadenopathy , disease , sarcoma , immunology , antibody , polyneuropathy , autoantibody
Castleman disease is a rare lymphoproliferative disease also known as angiofollicular lymph node hyperplasia. It is classified as hyaline vascular and plasmacytic variants histologically but characteristics of both types can coexist. Most unicentric cases of the disease are hyaline vascular while most multicentric cases are of the plasmacytic type. Although the pathogenesis is not completely understood, the role of interleukin (IL)-6 in unicentric disease and the roles of IL-6 and human herpes virus-8 in multicentric disease are well defined. Unicentric disease is typically localized and symptoms are minimal and treated locally. Multicentric disease is systemic and clinically characterized by generalized lymphadenopathy, splenomegaly, anemia, and systemic inflammatory symptoms. Systemic therapies are primarily given. Several malignant diseases including lymphomas, POEMS syndrome, follicular dendritic cell sarcomas, paraneoplastic pemphigus, Kaposi sarcoma, and amyloidosis can be associated with Castleman disease. In this paper, recent information about Castleman disease, which is a rare disease, is summarized.